Eric Ostertag, Poseida CEO (via website)

Mov­ing past a pa­tient death, Po­sei­da of­fers an ear­ly snap­shot of proof of ef­fi­ca­cy for a next-gen sol­id tu­mor CAR-T

Ten months af­ter the FDA took the shack­les off Po­sei­da’s study for a CAR-T di­rect­ed against cas­trate-re­sis­tant prostate can­cer, the ex­ec­u­tive team is now rolling out an ear­ly snap­shot of the proof-of-con­cept da­ta it’s look­ing for in a small, ear­ly-stage study.

Test­ed in 9 heav­i­ly pre-treat­ed pa­tients — with an av­er­age of 6 pri­or ther­a­pies — in­ves­ti­ga­tors tracked a sig­nif­i­cant, 50%-plus drop in PSA lev­els in 3 of those pa­tients and what they called a “con­cor­dant” imag­ing re­sult for tu­mor ef­fect. One pa­tient had a com­plete re­sponse — the ide­al re­sult for any can­cer study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.